A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

BACKGROUND: Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goals in this palliative setting is to develop chemotherapy-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grunenberg, Alexander, Kaiser, Lisa M., Woelfle, Stephanie, Schmelzle, Birgit, Viardot, Andreas, Möller, Peter, Barth, Thomas F. E., Muche, Rainer, Dreyhaupt, Jens, Raderer, Markus, Kiesewetter, Barbara, Buske, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243426/
https://www.ncbi.nlm.nih.gov/pubmed/34187401
http://dx.doi.org/10.1186/s12885-021-08464-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243426/
https://www.ncbi.nlm.nih.gov/pubmed/34187401
http://dx.doi.org/10.1186/s12885-021-08464-6

Ejemplares similares